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SummaryThe main objective of antifibrotic treatment is to avoid the complications
of chronic liver disease where its cause cannot be treated. Three main therapeutic
endpoints can be targeted: cause; comorbidity; and fibrosis. Antifibrotic treatment
is any intervention independent of cause that is intended to modify the course
and/or level of fibrosis through direct action on the mechanisms of fibrosis. Several
modalities are here considered: reduction of fibrosis course; reversion of fibrosis;
and reversion of cirrhosis. Semiquantitative histological staging and morphometry
are complementary techniques for monitoring fibrosis. The degree of fibrosis should
preferentially be estimated by fibrosis progression based on measurements taken at
baseline and during treatment, rather than by raw static measurements. Surrogate
markers are the only tools for assessing drug efficacy in clinical practice, and are
especially useful for checking compliance and identifying poor or non-responders.
We propose to define non-response as no decrease in fibrosis progression. The
renin–angiotensin system is a good candidate target for antifibrotic treatment, and
angiotensin-II type-1 receptor blockers, such as sartans, are probably effective.
Clinical trials are currently ongoing using marketed drugs, while new multitargeted
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